Drugs / ACP-204
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07029581 | Aug 2025 → Feb 2028 expected | Lewy body dementia | ACADIA Pharmaceuticals Inc. | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06159673 | Nov 2023 → Jan 2028 expected | Alzheimer disease | ACADIA Pharmaceuticals Inc. | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07095465 | Nov 2025 → Feb 2029 expected | Lewy body dementia | ACADIA Pharmaceuticals Inc. | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06194799 | Apr 2024 → Apr 2029 expected | Alzheimer disease | ACADIA Pharmaceuticals Inc. | Enrolling by invitation | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-07-20 | ACADIA Pharmaceuticals Inc. | Regulatory Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis acadia.com ↗
This is an important milestone for the remlifanserin program, and we look forward to sharing upcoming topline data from the RADIANT Phase 2 trial as we continue to advance remlifanserin as a potential new treatment option for patients and families impacted by this devastating condition. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-20 | ACADIA Pharmaceuticals Inc. | Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis acadia.com ↗ |
| 2023-11-27 | ACADIA Pharmaceuticals Inc. | Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis acadia.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACP-204 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07029581 ↗ |
| Action | Inhibit | “potent and selective antagonist/inverse agonist of 5-hydroxytryptamine (serotonin) receptor subtype 2A” NCT06159673 ↗ |
| Route | Oral | “Provided as 1 capsule, to be taken orally once daily” NCT07029581 ↗ |